-
1 . Academic Journal
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
- 저자
- by Kambugu, Andrew; Kaimal, Arvind; Castelnuovo, Barbara; Kiiza, Daniel; Asienzo, Jesca, et al.
- 소스
- In The Lancet HIV June 2022 9(6):e381-e393
-
-
7 . Periodical
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
- 저자
- by Paton, Nicholas I; Musaazi, Joseph; Kityo, Cissy; Walimbwa, Stephen; Hoppe, Anne, et al.
- 소스
- The Lancet HIV; June 2022, Vol. 9 Issue: 6 pe381-e393, 13p
-
7 . Periodical
Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial
- 저자
- by Mallewa, Jane; Szubert, Alexander J; Mugyenyi, Peter; Chidziva, Ennie; Thomason, Margaret J, et al.
- 소스
- The Lancet HIV; May 2018, Vol. 5 Issue: 5 pe231-e240, 10p